[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spondylarthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spondylarthritis":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,59,86,118,145,170,198,239,266],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":37,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100598885","eacvi-study-on-multimodality-cardiovascular-imaging-of-inflammatory-cardiovascular-diseases-100598885",false,"NCT07077304","EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","EACVI-INFLAME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide informed non-opposition\n3. Referred for a CMR and\u002For nuclear imaging exam\n\nAND a suspicion of one of the following ICARDs :\n\n1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)\n2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)\n3. Suspected Tako-Tsubo\n4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)\n5. Suspected Connective tissue disease with cardiovascular involvement:\n\n   * Systemic sclerosis\n   * Systemic lupus erythematosus\n   * Antiphospholipid syndrome\n   * Idiopathic inflammatory myopathies\n   * Rheumatoid arthritis, spondylarthritis\n6. Suspected Vasculitis with cardiovascular involvement:\n\n   * Small-vessel vasculitis (ANCA…)\n   * Large vessel vasculitis (Behcet disease, Takayasu…)\n7. Suspected Inflammatory disease with cardiovascular involvement:\n\n   * Sarcoidosis\n   * Still disease\n\nExclusion Criteria:\n\n1. Inability to provide non-opposition\n2. History of heart transplant","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms.\n\nDiagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights.\n\nGiven the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and\u002For cardiac PET in a multicentric international cohort.",[24,25,26,27,28,29,30,31,32,33,34,35,36],"Myocarditis","ANCA Associated Vasculitis","Pericarditis","Systemic Sclerosis","Systemic Lupus Erythematosus","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondylarthritis","Behcet Disease","Takayasu Arteritis","Sarcoidosis","Still Disease","Tako Tsubo Cardiomyopathy",[38,39,40,41,42,43,44,45],"Cardiovascular disease","Auto-immune disease","Auto-inflammatory disease","Rheumatic disease","CMR","PET","multimodality imaging","ICARD","RECRUITING","2026-06-03",{"date":49,"type":50},"2026-06-05","ACTUAL",{"date":52,"type":50},"2025-11-19",{"date":54,"type":20},"2028-10-30",{"name":56,"class":57},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100623272","study-of-the-association-between-sacroiliitisaxial-spondylarthritis-and-giant-cell-arteritis-polymyalgia-rheumatica-100623272","NCT07394478","Study of the Association Between Sacroiliitis\u002FAxial Spondylarthritis and Giant Cell Arteritis\u002F Polymyalgia Rheumatica","Study of the Association Between Sacroiliitis\u002FAxial Spondylarthritis and Giant Cell Arteritis\u002F Polymyalgia Rheumatica: A Case-control Observational Study","SAGE PPR","Inclusion Criteria:\n\n* Experimental group: Adult patient with spondylitis associated with GCA or PMR Control group: Adult patient with GCA or PMR\n\nExclusion Criteria:\n\n* Refusal to participate\n* Positive anti CCP",{"count":68,"type":20},10,"The purpose of the study is to recruit as many patients as possible presenting with sacroiliitis or authentic axial spondylarthritis and giant cell arteritis. The investigators will also be interested in the association of spondylarthritis and polymyalgia rheumatica given the continuum between these two pathologies. The aim is to investigate whether there is an association between giant cell arteritis and spondylarthritis or polymyalgia rheumatica and spondylarthritis.",[71,31,72],"Giant Cell Arteritis (GCA)","Polymyalgia Rheumatica",[71,31,74],"Polymyalgia rheumatica","NOT_YET_RECRUITING","2026-02-03",{"date":78,"type":50},"2026-02-06",{"date":80,"type":20},"2026-02-01",{"date":82,"type":20},"2026-06-30",{"name":84,"class":57},"Hôpital NOVO",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100595588","effects-of-a-digital-exercise-intervention-on-sleep-and-physical-activity-in-patients-with-spondyloarthritis-100595588","NCT07034404","Effects of a Digital Exercise Intervention on Sleep and Physical Activity in Patients With Spondyloarthritis","Effects of a Digital Adapted Physical Activity Program on Physical Activity Levels and Sleep Quality in Patients With Spondyloarthritis: A Randomized, Controlled, Multicenter Study.","ASPIRE","Inclusion Criteria:\n\n* Adults aged 18 to 80\n* Followed in rheumatology for axial spondyloarthritis validating the ASAS or modified New York criteria at all stages of progression,\n* Physically inactive (less than 150 minutes of moderate-intensity leisure-time physical activity per week), assessed at inclusion using the Global Physical Activity Questionnaire (GPAQ).\n* With stable treatment for 3 months\n* Signed informed consent\n* Membership of a social security scheme\n* Have access to a digital tool with an internet connection (tablet or smartphone)\n\nExclusion Criteria:\n\n* Concurrent impairment by another osteoarticular pathology interfering with mobility of the spine or lower limbs,\n* Central or peripheral neurological damage,\n* Hip, knee or ankle arthroplasty performed or scheduled within 18 months,\n* Any contraindication to physical activity (unstable or poorly controlled coronary ischaemia, severe asthma or significant obstructive ventilatory disorder (FEV1\u002FFVC \\\u003C 70%, FEV1 \\\u003C 60% predicted), musculoskeletal pathology interfering with physical activity, proliferative retinopathy, macroscopic proteinuria, poorly controlled hypertension, etc.).\n* Patients who do more than 150 minutes of moderate-intensity vigorous physical activity per week as part of their leisure activities.\n* Persons covered by articles L1121-5 to L1121-8 of the Public Health Code\n* Staff with a hierarchical link to the principal investigator\n\nNon-inclusion criteria related to physical activity :\n\n* Body mass index \\>35 kg\u002Fm2\n* History of chest pain during physical activity\n* History of sudden death in a first-degree relative\n* History of thoracic irradiation","80 Years",{"count":96,"type":20},100,"INTERVENTIONAL",[99],"NA","The goal of this clinical trial is to assess whether a tailored digital Adapted Physical Activity (APA) program can improve physical activity levels and sleep quality in adults diagnosed with spondyloarthritis (SpA).\n\nThe main questions it aims to answer are:\n\nDoes participation in a 6-month digital APA program increase average daily step count (measured with an activity tracker)? Does the program improve sleep quality (measured with the Pittsburgh Sleep Quality Index)? Researchers will compare participants receiving general physical activity advice (control group) to those following a structured digital APA program (intervention group) to see if the tailored digital support leads to better outcomes.\n\nParticipants will:\n\nComplete baseline assessments including physical activity, sleep, pain, and quality of life measures.\n\nBe randomly assigned to a control group or intervention group. For the intervention group, follow an individualized exercise program delivered through a virtual platform with support from an APA professional over 10 virtual sessions.\n\nWear a connected activity tracker (Withings) to monitor physical activity throughout the study.\n\nComplete follow-up assessments at 6 and 12 months.",[31,102],"Spondylarthropathies; Spondylitis, Ankylosing",[104,105,106,107],"exercise","physical activity","sleep quality","digital intervention","2025-06-25",{"date":110,"type":50},"2025-06-29",{"date":112,"type":20},"2025-07-01",{"date":114,"type":20},"2028-09",{"name":116,"class":57},"University Hospital, Grenoble",3,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":128,"conditions":129,"keywords":134,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":58},"100592813","spondylo-arthritis-screening-tool-among-patient-suffering-from-inflammatory-bowel-disease-100592813","NCT06998316","Spondylo-arthritis Screening Tool Among Patient Suffering From Inflammatory Bowel Disease","Linguistical Validation of a Spondylo-arthritis Screening Tool for Patients Suffering From Inflammatory Bowel Disease","QUESAM","Inclusion Criteria:\n\n* Patient with an inflammatory bowel disease according to gastroenterologist\n\nExclusion Criteria:\n\n* No exclusion criteria\n* Difficulty for understanding or reading french\n* Persons covered by articles L1121-5 to L1121-8 of the French Public Health Code\n* Patients with no social security coverage.\n* Patients refusing to participate voluntarily.",{"count":127,"type":20},220,"The QUESAM study aims to translate into French and validate the traduction of 2 screening questionnaires for spondylo-arthritis among people with inflammatory bowel disease.\n\nDETAIL (DETection of Arthritis in Inflammatory boweL diseases) and IBIS-Q (Inflammatory Bowel disease Identification of Spondyloarthritis Questionnaire) questionnaires are built to determine which patients might benefit from a rheumatologic consultation, for a potential rheumatologic inflammatory disease.\n\nThe investigators will translate the 2 questionnaire in french thanks to an external translation company, from english to french, then back to english to make sure the translation is correct.\n\nThen, the main question is:\n\nis there a conceptual and semantic equivalence beetween the original english questionnaire and the french-translated one.\n\nParticipant will answer the 2 screening questionnaire, one initial time during a consultation, and a second time after 1 month.",[31,130,131,132,133],"Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis","Spondylitis, Ankylosing",[135,131,132,130,136],"spondylarthritis","screening tools","2025-05-21",{"date":139,"type":50},"2025-05-31",{"date":141,"type":20},"2025-05",{"date":143,"type":20},"2026-07",{"name":116,"class":57},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":154,"targetDuration":155,"studyType":21,"phases":4,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":58},"100571447","observational-prospective-turkish-inception-cohort-of-uveitis-and-spondyloarthritis-100571447","NCT06720376","Observational Prospective Turkish Inception Cohort of Uveitis and Spondyloarthritis","Assessment of Spondyloarthritis in an Acute Anterior Uveitis Inception Cohort: a Cross Sectional and Prospective Comparative Study of HLA-B27-positive and -negative Cases","OPTICUS","Inclusion Criteria:\n\n* patients with uveitis\n\nExclusion Criteria:\n\n* patients diagnosed spondyloarthiritis before from the uveitis attack\n* patients with infectious uveitis","75 Years",{"count":96,"type":20},"5 Years","Spondyloarthritis (SpA) encompasses a group of inflammatory rheumatic diseases characterized by axial and\u002For peripheral arthritis, along with extra-articular manifestations such as enthesitis, dactylitis, uveitis, and skin lesions. Axial spondyloarthritis (axSpA), the hallmark of which is chronic sacroiliitis, can progress to vertebral fusion (\"bamboo spine\") in advanced cases. The prevalence of axSpA varies globally, ranging from 0.1% to 1.4%, with a higher incidence in men and a typical onset in the second or third decades of life. Diagnostic approaches include imaging techniques such as sacroiliac MRI and radiographs, alongside clinical criteria like inflammatory back pain, NSAID responsiveness, peripheral arthritis, and HLA-B27 positivity. Disease management primarily involves NSAIDs, with biologics used for refractory cases, and disease activity is monitored using indices such as BASDAI and ASDAS.\n\nAcute anterior uveitis (AAU) is the most common extra-articular manifestation of SpA, particularly associated with HLA-B27 positivity. It often presents unilaterally with redness, pain, and photophobia but can lead to severe complications if inadequately treated. Around 50% of patients with HLA-B27-positive AAU have underlying SpA, and the prevalence of uveitis increases with longer disease duration. While the link between SpA and AAU is well-established, further research is needed to determine optimal systemic treatment and follow-up protocols. This study aims to assess the prevalence and clinical characteristics of SpA in patients presenting with AAU at ophthalmology clinics.",[31,158],"Uveitis, Anterior",[160],"Spondylarthritis, Acute Anterior Uveitis, Inflammatory Back Pain, HLA-B27","2024-12-03",{"date":163,"type":50},"2024-12-06",{"date":165,"type":50},"2023-01-15",{"date":167,"type":20},"2030-01-15",{"name":169,"class":57},"Marmara University",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":97,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":85},"100540750","mid--or-high-flex-rods-versus-low-flex-rods-of-spineshape-system-iv-for-treatment-of-degenerative-lumbar-spine-diseases-100540750","NCT06320899","Mid- or High-flex Rods Versus Low-flex Rods of SpineShape System IV for Treatment of Degenerative Lumbar Spine Diseases","Mid- or High-flex Rods Versus Low-flex Rods of SpineShape System IV for Treatment of Degenerative Lumbar Spine Diseases - a Prospective, Multicenter, Randomized Controlled Non-inferiority Study","Inclusion Criteria:\n\n* degenerative symptoms in 1 to 2 segments in the lumbar spine L1-S1\n* signed informed consent of participant\n* confirmation of the participant that the attendance of follow-up visits are intended\n* Body-Mass-Index \\\u003C 32\n* Pedicle screw axis distance \\\u003C 30mm\n* one or more of the following indications:\n\n  * (dynamic) stenosis in the spinal canal\n  * neuroforaminal stenosis\n  * facet joint syndrome \u002F spondylarthrosis\n  * discopathy (recurrent disc hernia)\n  * degenerative spondylolisthesis (Meyerding \\\u003C1)\n  * instability (hypermobility with antelishtesis, hypomobility with retrolisthesis if decompressed)\n\nExclusion Criteria:\n\n* missing bone structure, e.g. due to congenital anomalies or sever anatomical deformities that make anchoring of the implant impossible\n* damaged structural tissue, e.g. due to a bone fracture\n* application to the thoracic or cervical spine\n* pronounced idiopathic scoliosis\n* spondylolisthesis \\> Meyerding grad 1\n* isthmic spondolylysis\n* bone tumor\n* osteochondrosis modic type I, II or III\n* osteoporosis, which could impair screw anchoring\n* history with third party implants\n* patients with an active local or systemic infection\n* known allergy to titatnium alloys\n* skeleton in growth (epiphyseal joints not closed)\n* severe muscular neuronal or vascular disease\n* immunosuppresive therapy\n* long-term therapy with cortisone\n* heavy smokers (regular consumption of more than six cigarettes per day), drug addicts and alcoholics\n* chronic pain patients\n* incapable of judgment or emergency situation\n* implantation during pregnancy","99 Years",{"count":179,"type":20},126,[99],"The purpose of this multi-center, randomized, clinical study is to show that the treatment of degenerative lumbar spine with high- or mid-flex rods is not inferior to the treatment with low-flex rods in terms of clinical and safety-related results.\n\nThe primary aim is to compare the reduction in back pain after the treatment with high- or mid-flex rods with that after treatment with low-flex rods. Secondary, the functionality after treatment with high- or mid-flex rods will be compared to that after treatment with low-flex rods.",[183,184,31,185,186,187],"Degenerative Lumbar Spinal Stenosis","Facet Joint Arthrosis","Discopathy","Degenerative Spondylolisthesis","Instability Lumbar Spine","2024-06-21",{"date":190,"type":50},"2024-06-25",{"date":192,"type":50},"2024-06-04",{"date":194,"type":20},"2031-08-31",{"name":196,"class":197},"SpineSave AG","INDUSTRY",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":206,"sex":16,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":97,"phases":210,"briefSummary":211,"conditions":212,"keywords":221,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":85},"100551493","axsend-exploring-immune-and-microbiota-effects-of-a-partial-enteral-nutrition-diet-in-axial-spondyloarthritis-100551493","NCT06460805","axSEND: Exploring Immune and Microbiota Effects of a Partial Enteral Nutrition Diet in Axial Spondyloarthritis","axSEND: Exploring Immune and Microbiota Effects of a Partial Enteral Nutrition Diet in People With Axial Spondyloarthritis","axSEND","Eligibility Criteria for Participants with axSpA\n\nInclusion criteria. Participants will fulfil ALL of the following:\n\n* Diagnosis of axSpA (fulfilling the ASAS criteria)\n* Active disease (BASDAI score ≥4) on day of study visit\n* Stable on treatment \\[defined as (1) no major change to therapy (change in treatment type) in the preceding 3 months AND (2) no minor change in therapy (adjustment of treatment dosage) in the preceding 1 month\\]\n* Age ≥ 16 years\n* Willing and able to give informed written consent.\n\nExclusion. Participants will have NONE of the following:\n\n* Pregnancy or breastfeeding\n* Prior diagnosis of IBD\n* Recipient of chemotherapy\u002Fimmunotherapy\u002Fradiotherapy in prior 3 months\n* Recent systemic antibiotic use (within last 1 month)\n* Current eating disorder\n* Food allergy incompatible with diet (e.g. cow's milk allergy)\n* Following a vegan diet\n* Major surgery in prior 3 months or planned in forthcoming 3 months.\n* Unable or unwilling to give informed consent\n* Unable or unwilling to try the PEN diet.\n\nEligibility Criteria for Healthy Volunteer Participants\n\nInclusion criteria. Participants will fulfil ALL of the following:\n\n* Age ≥ 16 years\n* Current student and\u002For staff member at the University of Glasgow\n* Willing and able to give informed written consent\n\nExclusion. Participants will have NONE of the following:\n\n* Pregnancy or breastfeeding\n* Prior diagnosis of an immune-mediated inflammatory condition\n* Recipient of chemotherapy\u002Fimmunotherapy\u002Fradiotherapy in prior 3 months\n* Recent systemic antibiotic use (within last 1 month)\n* Current eating disorder\n* Food allergy incompatible with diet (e.g. cow's milk allergy)\n* Following a vegan diet\n* Major surgery in prior 3 months or planned in forthcoming 3 months.\n* Unable or unwilling to give informed consent\n* Unable or unwilling to try the PEN diet.",true,"16 Years",{"count":209,"type":20},62,[99],"People with axial spondyloarthritis (axSpA) often have intestinal inflammation and intestinal microbiome dysbiosis, with some similarities to Crohn's-like inflammatory bowel disease (IBD) gut inflammation. However, research has not addressed whether Partial Enteral Nutrition (PEN), a diet formed of a liquid formula and some solid whole foods, which is effective at inducing remission in IBD, may influence the dysbiotic microbiome and inflamed, hyperpermeable intestine of axSpA patients, and whether these changes may be accompanied by alterations in systemic markers of inflammation. Thus, there is a need to determine the effects of PEN on these aspects in axSpA patients.\n\nIn this study, the investigators intend to trial a 2-week course (with optional additional 2-week extension) of a PEN diet in people with active axSpA disease. A group of healthy volunteers following the same diet will act as a control.",[213,214,215,216,217,218,31,219,220],"Axial Spondyloarthritis","Ankylosing Spondylitis","Inflammation","Dysbiosis","Arthritis","Spondylitis","SpA","AxSpA",[222,223,224,225,226,227,228,229],"Partial Enteral Nutrition","Nutrition","Axial spondyloarthritis","Ankylosing spondylitis","axSpA","Diet","PEN","AS","2024-06-13",{"date":232,"type":50},"2024-06-14",{"date":234,"type":50},"2024-04-25",{"date":236,"type":20},"2025-08-01",{"name":238,"class":57},"NHS Greater Glasgow and Clyde",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":247,"targetDuration":4,"studyType":97,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100537090","towards-telemonitoring-in-immune-mediated-inflammatory-diseases-implementation-of-a-mixed-attention-model-imidoc-100537090","NCT06273306","Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model (IMIDOC)","Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model","IMIDOC","Inclusion Criteria:\n\n* Clinical diagnosis with Rheumatoid Arthritis or Spondylarthritis\n* Treatment with biologic or targeted disease modifying antirheumatic drugs.\n* Ability to use smartphone.\n\nExclusion Criteria:\n\n* only patients with conditions that hinder or prevent the use of a mobile application (blindness, mental retardation, dementia, digitalfilliteracy).",{"count":248,"type":20},360,[99],"The main objective is to evaluate the implementation of a hybrid care model called the mixed attention model (MAM) in clinical practice and to evaluate whether its implementation improves clinical outcomes compared to conventional follow-up.\n\nThis is a multicenter prospective observational study involving 360 patients with rheumatoid arthritis (RA) and Spondylarthritis (SpA) from five Spanish Hospitals. Patients will be followed-up by the MAM protocol, which is a care model that incorporates the use of digital tool consisting of a mobile application (App) that patients can use at home and that professionals can review asynchronously to detect incidents and to follow their patients; clinical evolution between face-to-face visits. Another group of patients, whose follow-up will be conducted in accordance with a traditional face-to-face care model, will be assessed as the control group. Sociodemographic characteristics, treatments, laboratory parameters, assessment of tender and swollen joints, visual analogue scale for pain and electronic patient reported outcome reports (ePROs) will be collected for all subjects. In the MAM group, these items will be self-assessed both by the mobile App and during face-to-face visits with rheumatologist, who will do the same for patients included in the traditional care model. Patients will be able to report any incidence related to their disease or treatment through the mobile App.",[252,253,254,255,256,31],"Telemedicine","Telehealth","eHealth","Rheumatic Diseases","Arthritis, Rheumatoid","2024-02-15",{"date":259,"type":50},"2024-02-22",{"date":261,"type":20},"2024-03-15",{"date":263,"type":20},"2026-12-31",{"name":265,"class":57},"Instituto de Investigación Hospital Universitario La Paz",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":58},"100484785","il17-rate-and-spondyloarthritis-100484785","NCT05592574","IL17 Rate and Spondyloarthritis","Feasibility of an Il-17a Assay and Impact on Therapeutic Response in Patients With Active Axial Spondyloarthritis","Inclusion criteria\n\n* Patients with spondyloarthritis meeting the ASAS criteria\n* Patients who were to benefit from the implementation of a biological treatment after failure of at least two NSAIDs.\n* Patients having an active disease defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) higher than four,\n\nExclusion criteria\n\n* No predominant axial manifestation,\n* Having received a previous biological treatment\n* Patients presenting contraindication to the implementation of these treatments.","90 Years",{"count":275,"type":20},50,"There are, to date, no validated biomarkers or head-to-head RCTs of biologics to guide choice of biologic agent in axSpA. While there are now two head-to-head studies of a TNF inhibitor (TNFi) vs an IL-17 inhibitor (IL-17i) in psoriatic arthritis. Recommendations refers to biological DMARDs (bDMARDs) including TNFi and IL-17i for patients with high disease activity despite the use (or intolerance\u002Fcontraindication) of at least two non-steroidal anti-inflammatory drugs (NSAIDs) in axial SpA (axSpA) and in failure of a strategy including methotrexate for psoriatic arthritis. A tool to help us to decide which bDMARDs to use is necessary.\n\nIn SpA, the method of determination of IL17 seems to be questionable.\n\nThe determination of cytokines after stimulation of immune cells in patients with active SpA requiring a biological treatment could provide us with a tool to assist in the choice of therapy.\n\nThe aim of the study was to show the feasibility of cytokine assay following lymphocyte stimulation in active SpA requiring biological treatment. And secondly, to show the predictive character of this expression on the therapeutic response at three months after the implementation of a biological treatment.",[31],"2022-10-21",{"date":280,"type":50},"2022-10-24",{"date":282,"type":50},"2021-02-01",{"date":284,"type":20},"2041-01-31",{"name":286,"class":57},"Centre Hospitalier Universitaire de Nice"]